Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03038230 · ClinicalTrials.gov registry record · Phase 1
MCLA-117 in Acute Myelogenous Leukemia
A Phase 1 study, sponsored by Merus B.V..
- Terminated
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT03038230 is a Phase 1 study that was terminated before completion, run by Merus B.V.. The registered enrollment target is 80 participants.
The verdict
NCT03038230, a Phase 1 study, was terminated before completion, sponsored by Merus B.V..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
This is a First-in-Human, single arm, open-label, multi-national study designed to determine the safety, tolerability and preliminary efficacy of MCLA 117.
Interventions
- DRUG MCLA-117 bispecific antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2016-04 |
| Est. Completion | 2021-05-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03038230
The ClinicalTrials.gov registry entry for NCT03038230 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merus B.V., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MCLA-117 bispecific antibody is the first listed.
NCT03038230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03038230 about?
NCT03038230 is a clinical study titled "MCLA-117 in Acute Myelogenous Leukemia". This is a First-in-Human, single arm, open-label, multi-national study designed to determine the safety, tolerability and preliminary efficacy of MCLA 117.
What is the current status of trial NCT03038230?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2016-04. Estimated completion is 2021-05-11.
What interventions are being tested in trial NCT03038230?
The interventions under investigation include: MCLA-117 bispecific antibody (DRUG).
Who is sponsoring clinical trial NCT03038230?
This trial is sponsored by Merus B.V., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.